Sangamo Therapeutics, Inc SEC filings SGMOQ
Sangamo Therapeutics, Inc has 1,000 filings in SEC EDGAR's recent list, going back to Feb 5, 2013. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on May 14, 2026, covering the quarter ended Mar 31, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 12, 2025 |
| DEF 14A | Proxy statement | Apr 19, 2024 | Jun 4, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 3, 2024 | Jun 4, 2024 |
| DEF 14A | Proxy statement | Apr 17, 2023 | — |
| PRE 14A | Preliminary proxy statement | Apr 5, 2023 | — |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 1, 2022 | May 24, 2022 |
| DEF 14A | Proxy statement | Apr 2, 2021 | May 25, 2021 |
| DEFA14A | Additional proxy material | May 8, 2020 | — |
| DEF 14A | Proxy statement | Apr 2, 2020 | May 18, 2020 |
| PRE 14A | Preliminary proxy statement | Mar 23, 2020 | May 18, 2020 |
| DEFA14A | Additional proxy material | Apr 25, 2019 | — |
| DEF 14A | Proxy statement | Apr 25, 2019 | Jun 10, 2019 |
| DEFA14A | Additional proxy material | Apr 24, 2018 | — |
| DEF 14A | Proxy statement | Apr 24, 2018 | Jun 11, 2018 |
| DEFA14A | Additional proxy material | Apr 25, 2017 | — |
| DEF 14A | Proxy statement | Apr 25, 2017 | Jun 5, 2017 |
| DEFA14A | Additional proxy material | Jun 1, 2016 | — |
| DEFA14A | Additional proxy material | Apr 25, 2016 | — |
| DEF 14A | Proxy statement | Apr 25, 2016 | Jun 14, 2016 |
| PRE 14A | Preliminary proxy statement | Apr 12, 2016 | Jun 14, 2016 |
| DEFA14A | Additional proxy material | May 8, 2015 | — |
| DEF 14A | Proxy statement | Apr 28, 2015 | Jun 22, 2015 |
| DEF 14A | Proxy statement | Mar 11, 2014 | Apr 21, 2014 |
| PRE 14A | Preliminary proxy statement | Feb 28, 2014 | Apr 21, 2014 |
| DEF 14A | Proxy statement | Apr 25, 2013 | Jun 12, 2013 |
Showing 26 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SGMOQ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Richmond, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1001233
- Former names
- SANGAMO BIOSCIENCES INC (until Jan 6, 2017)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.